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ABSTRACT 
 
 
Background: Proton pump inhibitors (PPIs) are associated with acute tubulointerstitial 
nephritis, and there are reports associating their use with the development of chronic kidney 
disease (CKD).  
 
Aim: To determine if PPI use is associated with major adverse renal events (MARE) in 
patients with CKD. 
 
Design: Observational cohort study comprising patients with CKD attending secondary care 
renal clinics from 01/01/2006 until 31/12/2016.   
 
Methods: We collated baseline clinical, socio-demographic and biochemical data at start of 
PPI (PPI group) or study inception (control group). MARE was considered a composite of 
doubling of creatinine or end stage renal disease. Association between PPI exposure and 
progression to MARE was assessed by cause-specific hazards competing risk survival 
analysis. 
 
Results: There were 3,824 patients with CKD included in the analyses of whom 1,195 were 
prescribed a PPI. The PPI group was younger (64.8 vs 67.0 years, p<0.001), with lower 
eGFR (30 vs 35 ml/min, p<0.001) and more proteinuria (64 vs 48 mg/mmol, p<0.001). PPI 
use was associated with progression to MARE on multivariable adjustment (HR 1.13 [95% 
confidence interval, CI 1.02-1.25], p=0.021). Other factors significantly associated with 
progression to MARE were higher systolic blood pressure (SBP), lower eGFR, greater 
proteinuria, congestive cardiac failure (CCF) and diabetes. Hypomagnesaemia was more 
common in the PPI group (39.5 vs 18.9 %, p<0.001). 
 
 
Conclusion: PPI use was associated with progression to MARE, but not death in patients 
with CKD after adjusting for factors known to predict renal progression, including lower 
eGFR, proteinuria and comorbidities.These findings require to be validated in a prospective 
study.  . 
 
KEY WORDS 
 
Nephrology, Epidemiology, Pharmacology 
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INTRODUCTION 
 
Chronic kidney disease (CKD) is estimated to affect a tenth of the world’s population and the 
prevalence is increasing (1, 2). Many patients will experience a graded decline in renal 
function over time with a minority developing end stage renal disease (ESRD), necessitating 
renal replacement therapy (RRT) (3, 4). The increasing burden of CKD at population level 
combined with the substantial costs of ESRD to the individual demands focus upon  factors 
implicated in the progression of renal disease. 
 
Proton pump inhibitors (PPIs) are commonly prescribed medications, which lead to an 
effective reduction in gastric acid secretion and are advocated for short term use in 
dyspeptic conditions(5, 6). These medications, however, are often prescribed for prolonged 
periods without a clear indication (7), and extended use can lead to a range of adverse 
effects including hypomagnesaemia(8).  
 
PPIs have been shown to be associated with acute kidney injury (AKI) through interstitial 
nephritis(9-12), however, recent evidence suggests that there may be an association 
between PPIs and the development and progression of CKD(13-18) presumably via other, 
currently unexplained, mechanisms. Lazarus et al found that when compared to histamine 
receptor blocker (H2RB) users, PPI users had an approximate fifty percent increased risk of 
incident CKD(13). Similar findings were produced by Xie et al who demonstrated a graded 
relationship between duration of PPI exposure and poor renal outcomes(14). These results 
were further supported by a recent systematic review which found that PPI users 
experienced more AKI, incident CKD and ESRD(19). However, the mechanisms 
underpinning progressive renal impairment in such patients remain unclear and are unlikely 
to be linked to tubulointerstitial nephritis, which occurs in an acute and idiosyncratic manner. 
Recent evidence also fails to support that episodes of intervening AKI account for the 
progressive decline in renal function seen in such patients(15).  
 
Furthermore, considerable uncertainty exists within the observational data. The majority of 
previous inquiries fail to account for several important covariates(19). Although a biological 
gradient has been implicated in some studies(13, 14, 18), others have found an inverse 
association between PPI exposure and adverse renal outcomes with prolonged courses of 
treatment(14, 17). All previous cohort studies have focused upon a general population cohort 
of patients; the results of which may not therefore be extrapolated to patients with CKD. 
Furthermore, evidence of poorer outcomes in upper gastrointestinal dyspeptic conditions in 
patients with CKD and ESRD requires judicious use of PPIs in high risk patients(20-22). A 
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lack of experimental data combined with a paucity of observational studies of variable quality 
yields considerable uncertainty(19). The widespread availability and use of PPIs in this 
context necessitate further study. 
 
We aimed to determine if PPI use is associated with adverse renal outcomes or survival in 
patients with CKD. We hypothesised that PPI use would be independently associated with 
progression of CKD, but not mortality. 
 
 
MATERIALS AND METHODS 
 
 
Study Design 
 
We conducted a retrospective observational cohort study of patients with CKD referred to a 
secondary care renal clinic between 1st January 2006 and 31st December 2016. The cohort 
was subdivided into a PPI group who were prescribed a PPI for the first time at any time 
during the study period and a non-PPI group who had never received a PPI. Data were 
derived from a prospectively collated electronic health record (EHR). 
 
The study did not require formal ethical approval as patient identifiable data was not used in 
the analyses, however, the study was approved by the Caldicott Guardian for NHS Greater 
Glasgow and Clyde (GGC). 
 
Setting and Participants 
 
The cohort derived adults (over 16 years) with CKD (eGFR < 60ml/ min/1.73m2) who had 
been referred to a large renal service covering a population of 1.2 million people living in a 
mix of urban and rural areas. We collected baseline exposure variables at the start of PPI 
(PPI group) or study inception (non-PPI group). Patients were then followed up inclusively 
until primary outcome, death or censorship at the end of follow up (28th February 2018). 
 
Patients were excluded for historic or baseline PPI use, development of the primary outcome 
prior to recorded PPI use or missing urinary protein:creatinine ratio (uPCR) or systolic blood 
pressure (SBP) data. 
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Exposure Measurements 
 
Patients with PPI listed in the medicines list within the EHR were included in the intervention 
group. High dose PPI was defined as greater than or equal to omeprazole 40mg once daily 
(OD) or lansoprazole 30mg OD dose equivalent. Baseline data included age, sex, 
biochemistry, angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker 
(ARB) prescription, SBP and diastolic blood pressure (DBP), uPCR and past medical history. 
eGFR was determined using the CKD-EPI equation(23). Prevalent co-morbidities, including 
congestive cardiac failure (CCF), were noted at time of inception within the EHR. The 
Scottish Index for Multiple Deprivation (SIMD) is a multi-dimensional area level measure of 
deprivation based upon patients’ postcode of residence(24, 25).  
 
Outcome Measurement 
 
The primary outcome was a composite measure of doubling baseline creatinine or ESRD 
denoted Major Adverse Renal Events (MARE). ESRD was defined as the commencement of 
renal replacement therapy (i.e. dialysis or transplant).  
 
Secondary outcomes included hypokalaemia (</= 3.4mmol/L), hypomagnesaemia (</= 
0.64mmol/L), hypocalcaemia (</= 2.09mmol/L) adjusted for albumin and hypereosinophilia 
(>/= 0.4 x 109/L) which were defined at any time during follow-up. 
 
Statistical Analysis 
 
Data were summarised with mean and standard deviation for normally distributed and 
median and interquartile ranges for non-normally distributed data. Categorical data was 
summarised by proportions and frequencies. Differences between the PPI and non-PPI 
groups were analysed by a Chi2, two sample T-test, Wilcoxon rank sum or Kruskal-Wallis 
test. Patients with large proportions of missing data (> 10%) of a critical baseline exposure 
measurement were excluded from the analysis. 
 
A survival analysis was performed to compare the risk of MARE and death between the PPI 
and non-PPI groups. We constructed a cause specific multivariable hazards model to 
explore the impact of PPI use on MARE with the competing risk of death(26). The model 
covariates were selected on the basis of biological plausibility. The final model was 
constructed via backward stepwise selection with exposure variables sequentially removed 
based on their impact on the model. Statistical significance was determined by a P value of 
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less than 0.05. Interactions were not formally tested, but the potential relationship between 
co-variates was considered and correlation assessed for as appropriate.  
 
Data were analysed with MASS, CFC, cmprsk and cr17 packages for R statistical software 
version 3.5.0 in RStudio version 1.1.447. 
 
 
RESULTS 
 
 
There were 7,766 patients with CKD referred to a secondary care renal clinic during the 
study period. Figure 1 shows a consort diagram of patients included in the study. There were 
3,824 (49.2%) included in the final analyses of whom 1,195 were prescribed a PPI (31.3%).  
 
Figure 1 – Consort diagram of patients included in the study 
 
 
Table 1 describes the baseline characteristics of the PPI group, control group and the whole 
cohort. Sex differentiation, SIMD, baseline SBP and prevalence of CCF, peripheral vascular 
disease and stroke were similar in both groups. The PPI group was younger with lower 
eGFR, more proteinuria and greater prevalence of myocardial infarction (MI) and diabetes. 
ACE-inhibitor or ARB prescription were more common in the PPI group. 345 of 1,195 
patients received a high dose PPI (28.9%).  
 
Table 1 – Baseline characteristics of whole cohort, PPI and non-PPI groupsa 
 
Table 2 describes the primary and secondary outcomes of the PPI group, control group and 
the whole cohort. Median follow up for all patients was 5.6 years, but was longer in the PPI 
group. 1,741 patients died during follow up (45.5%) although there was no difference in 
mortality between each group. Hypomagnesaemia, hypocalcaemia and hypereosinophilia 
were more common in the PPI group as was MARE (55.5 vs 36.6%, p<0.001).  
 
Table 2 – Outcomes of whole cohort, PPI and non-PPI groupsb 
 
Figure 2 shows unadjusted survival curves and cumulative incidence functions for the 
progression to MARE and death in both groups. Patients who received a PPI were 
significantly more likely to experience MARE (log rank p<0.001). 
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Figure 2 – Unadjusted survival curves and cumulative incidence functions for the 
progression to MARE and death between PPI and non-PPI groups 
 
 
Table 3 shows the final model cause specific hazard ratio competing risk analysis for MARE. 
PPI use was associated with progression to MARE on multivariable adjustments (HR 1.13 
[95% CI 1.02-1.25], p=0.021). Other factors significantly associated with progression to 
MARE were higher SBP (HR 1.00 [95% CI 1.00-1.01], p=0.012), lower eGFR (HR 0.89 [95% 
CI 0.86-0.92], p<0.001), greater proteinuria (HR 1.02 [95% CI 1.01-1.02], p<0.001), CCF 
(HR 1.27 [95% CI 1.04-1.54], p<0.016) and diabetes (HR 1.38 [95% CI 1.25-1.53], p<0.001). 
 
Table 3 – Cause specific hazard ratio competing risk analysis for MARE 
 
 
DISCUSSION 
 
 
In our study of patients referred to a secondary care renal clinic over a ten-year period, 
patients receiving a PPI were They were more likely to experience electrolyte derangement 
and adverse renal outcomes, but not death.  
 
Our study is the first to elicit a positive association between PPI use and adverse renal 
outcomes in a CKD population. Lazarus et al assessed PPI and H2RB users for incident 
CKD amongst two general population cohorts the results of which may not necessarily be 
applicable to a CKD population. It is possible that the nephrotoxic potential of PPIs is 
affected by a priming effect of established CKD. They found an association between PPIs 
and incident CKD after adjustment for a large number of demographic, socioeconomic and 
clinical variables. Furthermore, they showed a graded relationship with a higher risk of 
incident CKD with twice daily PPI dosing(13). Similar findings were reported by Xie et al and 
Arora et al(14, 16).  
 
In assessing the potential causal relationship between PPIs and CKD we should consider 
the criteria established by Bradford-Hill(27). The case for causality is weakened by those 
studies which have paradoxically elicited an inverse graded relationship between PPI 
exposure in terms of drug dosing or duration of use and adverse renal outcomes(14, 17). In 
the only previous study to address this question in a population of patients with ESRD, Peng 
and colleagues’ case control design did not allow them to comment on any temporal 
relationship between PPI use and adverse outcomes. Furthermore, they paradoxically 
demonstrated a lower risk of ESRD with a larger defined daily dose of PPI(17). Xie and 
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colleagues’ finding of a graded association between PPI use and adverse renal outcomes 
which became inverse beyond 720 days raises questions about the biological plausibility of 
such a relationship(14). The lack of experimental evidence remains a significant barrier to 
conclusions of causal relationship between PPI use and progressive CKD. There are a 
number of proposed biological mechanisms to explain the nephrotoxic potential of PPIs 
including hypomagnesaemia and altered bowel microbiological flora(8, 28). Xie et al found 
that PPIs were independently associated with CKD progression even once episodes of 
intervening AKI were accounted for in their modelling(15). Others have suggested it is 
related to the accumulation of toxic breakdown products from PPI metabolism(29).  
 
Hypomagnesaemia is associated with both the progression of CKD and all-cause mortality in 
patients with renal disease(30, 31). There is both observational and experimental evidence 
that low magnesium contributes to vascular calcification in CKD through 
hyperphosphataemic mineral bone disease which is a proposed mechanism for progression 
to ESRD in such patients(32, 33). It is possible that any potential impact of PPIs in CKD is 
mediated by disordered magnesium homeostasis.  
 
This study has a number of strengths. Ours is the first cohort study in a CKD population 
within a European context. Our data was of high quality with use of validated exposure 
covariates. The data were collected prospectively thereby allowing temporality to be 
assessed between PPI use and renal outcomes, further enhanced by our use of a ‘new user 
design’, which removed the potential for misclassification bias from previous PPI exposure. 
We had the advantage of prolonged follow up with no loss to follow-up. Ours was also an 
unselected, representative sample of patients with CKD which should be generalisable to an 
equivalent metropolitan setting. Our use of the SIMD quintiles allowed us to assess the 
impact of socioeconomic status on renal outcomes. Finally, the cause specific hazards 
model employed allows time to event analysis which accounts for multiple outcomes 
including death. This reduced the effect of survival bias common to other observational 
studies.  
 
 
There are inevitable limitations. Firstly, the large number of patients excluded from the study 
risks selection bias; this could not be prevented due to the substantial proportion of missing 
data for imperative exposure covariates. There are also a variety of unmeasured covariates 
which could confound the observed associations including concurrent medications, episodes 
of AKI or hospitalisation and baseline hypomagnesaemia. Follow up time is longer in the PPI 
group which may bias towards adverse outcomes. The observational nature of the data 
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means that the possibility of residual confounding cannot be negated. Misclassification bias 
may have occurred for several reasons; over the counter availability of PPIs mean that 
patients could have purchased the medication without a prescription from a healthcare 
professional, whilst the accuracy of the EHR relies upon the reliability of medical 
documentation. In addition, it could be argued that the PPI and non-PPI groups were not well 
matched. Our study did not compare PPI and H2RB users as in previous studies, however, 
the groups were self-selected by PPI prescription via internal comparison. There are a 
number of reasons to believe that PPI users are generally a sicker group of patients who 
require greater use of health services therefore biasing the results towards a positive 
association with CKD which is in fact due to residual confounding.(13, 14, 34) 
 
We demonstrate a positive association between PPI use and adverse renal outcomes in a 
CKD population and are the first to do so. However, the impact of PPI use on the 
progression of CKD remains uncertain pending a prospective cohort study to validate these 
findings.  
 
CONCLUSION 
 
PPI use is associated with progression to adverse renal outcomes in patients with CKD after 
adjusting for factors known to predict renal progression. Our analysis is the first to assess 
any potential association in a CKD population and adds to the existing literature by 
supporting the positive association between PPI use and CKD progression observed in 
previous studies. The underlying mechanism by which PPI use contributes to CKD 
progression is not clear but may relate to disrupted magnesium homeostasis. 
 
 
Word Count (manuscript): 2,378 words (excluding abstract, references, tables and figures) 
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TABLES 
 
Table 1 – Baseline characteristics of whole cohort, PPI and non-PPI groups a 
 
Variable PPI group Control group Full group P value 
N= 1195 2629 3824   
Age (years)* 64.8 (13.1) 67.0 (14.6) 66.3 (14.2) <0.001 
Male  630 (52.7) 1399 (53.2) 2029 (53.1) 0.803 
SIMD* 2 (1-4) 2 (1-4) 2 (1-4) 0.245 
ACEi or ARB 901 (75.4) 1799 (68.4) 2700 (70.6) <0.001 
SCr** (umol/l) 219 (112) 176 (70) 190 (88) <0.001 
GFR** (ml/min) 30 (16) 35 (15) 33 (15) <0.001 
SBP** (mmHg) 144 (24) 147 (14) 146 (12) 0.270 
DBP** (mmHg) 75 (13) 76 (13) 76 (13) 0.001 
uPCR* (mg/mmol) 64 (30-182) 48 (20-129) 54 (23-143) <0.001 
CCF 78 (6.5) 177 (6.7) 255 (6.7) 0.813 
MI 295 (24.7) 492 (18.7) 787 (20.6) <0.001 
PVD  18 (1.5) 43 (1.6) 61 (1.6) 0.767 
Stroke 89 (7.4) 167 (6.4) 256 (6.7) 0.209 
Diabetes 454 (38.0) 871 (33.1) 1325 (34.6) 0.003 
aData are n (%) unless otherwise specified *median (IQR) **mean (SD) 
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Table 2 – Outcomes of whole cohort, PPI and non-PPI groups b 
 
Variable PPI group Control group Full group P value 
N= 1195 2629 3824   
Follow-up (years)* 6.2 (3.3) 5.3 (3.4) 5.6 (3.4) <0.001 
Hypereosinophilia 773 (64.7) 1468 (55.8) 2241 (58.6) <0.001 
Low K 646 (54.1) 1001 (38.1) 1647 (43.1) <0.001 
Low Mg  472 (39.5) 498 (18.9) 970 (25.4) <0.001 
Low Ca  485 (40.6) 605 (23.0) 1090 (28.5) <0.001 
Low K or Mg  736 (61.6) 1117 (42.5) 1853 (48.5) <0.001 
RRT required  265 (22.2) 183 (7.0) 448 (11.7) <0.001 
Double creatinine  663 (55.5) 963 (36.6) 1626 (42.5) <0.001 
MARE  663 (55.5) 963 (36.6) 1626 (42.5) <0.001 
Dead  567 (47.4) 1174 (44.7) 1741 (45.5) 0.116 
bData are n (%) unless otherwise specified *median (IQR) 
 
Table 3 – Cause specific hazard ratio competing risk analysis for MARE 
 
Variable HR [95% CI] P value 
Male sex 1.08 [0.98 - 1.19] 0.137 
Age a 1.02 [0.98 - 1.06] 0.254 
SBP b 1.00 [1.00 - 1.01] 0.012* 
eGFR c 0.89 [0.86 - 0.92] <0.001* 
uPCR d 1.02 [1.01 - 1.02] <0.001* 
PPI Use 1.13 [1.02 - 1.25] 0.021* 
CCF e 1.27 [1.04 - 1.54] 0.016* 
MI e 1.03 [0.91 - 1.16] 0.665 
PVD e 1.29 [0.87 - 1.93] 0.203 
Stroke e 1.11 [0.92 - 1.34] 0.289 
Diabetes e 1.38 [1.25 - 1.53] <0.001* 
a ten years, b ten mmHg, c ten ml/m, d 100 mg/ml, e present *statistical significance 
 
 
LEGENDS TO FIGURES 
 
Figure 1 – Consort diagram of patients included in the study 
 
Figure 2 – Unadjusted survival curves and cumulative incidence functions for the 
progression to MARE and death between PPI and non-PPI groups 
 
 
 
